Oral Solid Dosage Pharmaceutical Formulation Market Growth Outlook Reveals A CAGR Of 5.2% And A Market Value Of $846.37 Billion By 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Oral Solid Dosage Pharmaceutical Formulation Market Expansion From $692.14 Billion In 2026 To $846.37 Billion In 2030
The market for oral solid dosage pharmaceutical formulations has experienced notable expansion over the past few years. Projected to rise from $653.26 billion in 2025 to $692.14 billion in 2026, it reflects a compound annual growth rate (CAGR) of 6.0%. Several factors have driven growth during the historical period, including the broad adoption of oral drug delivery methods, well-developed manufacturing facilities for tablets and capsules, an increasing incidence of chronic conditions, the cost efficiency of oral solid dosage forms, and extensive regulatory experience with these formulations.
The market for oral solid dosage pharmaceutical formulations is projected to experience notable expansion over the coming years, reaching an estimated value of $846.38 billion by 2030, with a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period is fueled by factors such as the rising need for long-acting oral medications, an increased emphasis on patient adherence and convenience, the broadening of pharmaceutical outsourcing and CDMO activities, heightened worldwide generic drug production, and advancements in excipients and formulation technologies. Key trends shaping this timeframe encompass a greater adoption of controlled and modified-release dosage forms, a growing preference for patient-friendly oral solid options, the expansion of both generic and branded solid dosage manufacturing capabilities, a stronger focus on formulations with high bioavailability, and a shift toward cost-effective, scalable oral dosage production methods.
Download A Free Sample Report For Comprehensive Market Insights:
#Oral Solid Dosage Pharmaceutical Formulation Market Growth Factors: Which Forces Are Supporting Market Expansion?
A key driver behind the expansion of the oral solid dosage pharmaceutical formulation market is the growing occurrence of chronic diseases. These conditions are defined as long-lasting health issues that typically endure for three months or longer. Their increasing frequency can be attributed to aging populations, inactive lifestyles, unhealthy eating patterns, environmental influences, and advancements in detection and diagnostic techniques. Oral solid dosage forms play a crucial role in managing chronic illnesses and promoting consistent long-term treatment due to their convenience, stability, and accurate dosing capabilities. As an illustration, the World Health Organization, an intergovernmental body headquartered in Switzerland, reported in February 2024 that over 35 million new cancer cases are anticipated by 2050, marking a 77% rise from the estimated 20 million cases in 2022. Consequently, this upward trend in chronic disease prevalence is fueling demand within the oral solid dosage pharmaceutical formulation market.
Oral Solid Dosage Pharmaceutical Formulation Market Segment Analysis Highlighting Growth Areas
The oral solid dosage pharmaceutical formulation market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Controlled-Release Tablets, Effervescent Tablets, Chewable Tablets, Sublingual Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Liquid-Filled Capsules, Delayed-Release Capsules
3) By Powders And Granules: Oral Powders (Reconstitution), Granules (Oral Suspension Or Dispersible Granules)
4) By Lozenges And Pastilles: Medicinal Lozenges, Herbal Lozenges, Sugar-Free Lozenges, Pastilles ( Throat Or Cough Relief)
5) By Gummies: Vitamin Gummies, Herbal And Nutritional Supplement Gummies, Pharmaceutical Gummies ( Pain Relief Or Sleep Aids)
Oral Solid Dosage Pharmaceutical Formulation Market Industry Trends: What Changes Are Reshaping Demand?
Key players in the Oral Solid Dosage (OSD) pharmaceutical industry are prioritizing the creation of innovative approaches like fixed dose combinations to boost effectiveness, patient adherence, and safety. A fixed dose combination (FDC) refers to a drug containing two or more active substances combined into a single dosage form, designed to streamline therapy and enhance patient compliance. As an example, in February 2025, Ono Pharmaceutical Co. Ltd., a pharmaceutical firm based in Japan, secured approval from the U.S. Food and Drug Administration (FDA) for Journavex (suzetrigine) 50 mg oral tablets, indicated for managing moderate to severe acute pain in adults. This medication operates by selectively inhibiting NaV1.8 sodium channels within the peripheral nervous system, thereby interrupting pain signals before they can reach the brain, delivering effective pain relief while avoiding addiction-related dangers. Clinical studies revealed a substantial decrease in pain when compared to a placebo, accompanied by a safety profile that was generally well-received, with only mild side effects like itching and minor discomfort noted.
Oral Solid Dosage Pharmaceutical Formulation Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International
Access The Complete Oral Solid Dosage Pharmaceutical Formulation Market Report:
Oral Solid Dosage Pharmaceutical Formulation Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
